Iantrek Presents New Data for CycloPen System with AlloFlo Carriers

At the ASCRS meeting in Boston, Iantrek presented new data for its micro-interventional glaucoma surgical device CycloPen with AlloFlo.

CycloPen is Iantrek’s microinterventional system for the ab-interno construction, modification, reinforcement and repair of a cyclodialysis. AlloFlo (scleral spacer - 0.5 x 0.5 x 5 mm) is designed to naturally enhance uveoscleral outflow by utilizing bio-tissue for endoscleral reinforcement.

At ASCRS, the following two presentations were given demonstrating the potential benefits of the CycloPen with AlloFlo carriers:

"Imaging of a Supraciliary Allograft Implant after Cyclodialysis Reinforcement," by James S. Lewis, MD

• Anterion OCT imaging of bio-tissue implants in the angle demonstrated the allograft implant has homologous reflectivity to native endoscleral tissue and that the flexible allograft is conforming to the anatomic architecture of the endoscleral wall
• OCT findings after implantation of AlloFlo bio-tissue demonstrated 0 of 22 implants migrated throughout 12 months

"Endoscleral Allograft Bio-Tissue Stability, Tolerability, and Imaging of Cyclodialysis Bio-Reinforcement in Eyes with Glaucoma," by Arsham Sheybani, MD

• Interim analysis of real-world surgical outcomes with AlloFlo in 243 consecutive cases demonstrated favorable safety profile through 30 days post-op
• Ongoing registry (CREST Registry) with 250 eyes in the US and data up to 12 months 

"In my mind, solving uveoscleral outflow and the fibrosis that causes the procedure to fail will be a mini-paradigm shift if it occurs,” said Arsham Sheybani, MD. “Given my practice, I am hoping that we have a good uveoscleral option for patients who have failed TM or subconjunctival surgeries. A standalone suprachoroidal shunting procedure may provide an alternative option over a second tube or diode CPC in some patients."

Iantrek also presented a first-in-class micro-interventional solution addressing the trabecular outflow pathway that offers control, precision, and titratability. The solution is designed to offer controlled circumferential trabeculorrhexis via proprietary technology. It also expands the area of trabecular meshwork that can be treated via goniotomy.